Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Currently amended): A pharmaceutical composition comprising a macrelide T cell immunomodulator or immunosuppressant pimecrolimus in combination or association with a calciferel calcipotriol or tacalcitol together with at least one pharmaceutically acceptable diluent or carrier.

Claim 2. (Canceled)

Claim 3. (Currently amended): A method of treatment of <u>a condition selected from</u> a dermatological-disease-such as atopic dermatitis, acne or psoriasis, or <u>and</u> an inflammatory bowel disease (IBD), in a subject suffering from or at risk for such condition, <u>wherein said</u> <u>method comprises</u> co-administering a synergistically effective amount of a composition according to claim 1.

Claim 4. (Currently amended): A process for the preparation of a composition of claim 1 comprising mixing a macrolide T-cell immunomodulator or immunosuppressant pimecrolimus and a calciferol in combination or association with at least one pharmaceutically acceptable diluent or carrier.

Claim 5. (Currently amended): A kit of parts comprising a macrolide T-cell-immunomodulator or immunosuppressant pimecrolimus and a calciferol in separate unit dosage forms together with instructions for use.